Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial

The efficacy and field safety of marbofloxacin (Zeniquin) for the treatment of superficial and deep bacterial pyoderma were evaluated. Seventy-two dog s were treated with 2.75 mg kg(-1) of marbofloxacin orally once daily for 2 1 or 28 days. Sixty-two dogs (86%) had superficial pyoderma and 10 (14%) ha d deep pyoderma. A history of prior pyoderma was reported in 39/72 dogs. Pr etreatment aerobic bacteriologic cultures of skin lesions were performed in 47 cases and the predominant pathogen isolated was Staphylococcus intermed ius. Treatment was successful in 62/72 (86.1%) dogs, improvement was noted in 6/72 (8.3%) dogs and treatment failed in 4/72 (5.6%) dogs. Adverse effec ts associated with treatment included listlessness, anorexia, vomiting, sof t stool, flatulence and polydipsia; these adverse effects were seen in only 6/81 dogs. Marbofloxacin was safe and effective for the treatment of super ficial and deep pyoderma in dogs at the dosage used in this study.